Suvretta Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Suvretta Capital Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-692,000	Closed	-$21.2M	–	102
2022 Q1	$21.2M	Hold	692,000	–	–	0.65%	49
2021 Q4	$21.6M	Sell	692,000 -466,961	-40%	-$14M	0.42%	50
2021 Q3	$17.7M	Buy	1,158,961 +564,850	+95%	+$9.82M	0.3%	50
2021 Q2	$11.1M	Buy	594,111 +154,047	+35%	+$2.84M	0.17%	78
2021 Q1	$7.88M	Buy	+440,064	New	+$7.46M	0.12%	80

Other funds holding XENE

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Suvretta Capital Management's XENE Position: Q2 2022 in Review

Suvretta Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q2 2022, closing a stake of 692,000 shares — an estimated $21.2M sold.

Suvretta Capital Management first reported a position in XENE in Q1 2021 and held it in 5 quarters. The position peaked at $21.6M in Q4 2021. 151 funds tracked by Wall St. Rank hold XENE as of Q2 2022.

Suvretta Capital Management reported no remaining Xenon Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Suvretta Capital Management sold 692,000 Xenon Pharmaceuticals shares in Q2 2022, an estimated $21.2M.
Suvretta Capital Management first reported a position in Xenon Pharmaceuticals in Q1 2021 and held it in 5 quarters.
Suvretta Capital Management's Xenon Pharmaceuticals position peaked at $21.6M in Q4 2021.
151 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2022.

Based on Suvretta Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.